Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244134 | 1.00 | TAAR1 (0.49) | TAAR1AOC3NFKB1NPC1RAB9A | |
| SCHEMBL26819186 | 0.84 | NFKB1 (0.48) | NFKB1NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2246162 | 0.80 | EPHX2 (0.64) | TAAR1NPC1RAB9AEPHX2 | |
| SCHEMBL2246160 | 0.80 | EPHX2 (0.64) | TAAR1NPC1RAB9AEPHX2 | |
| SCHEMBL17799832 | 0.77 | APP (0.58) | TAAR1AOC3RXFP1KMT2APOLB | |
| SCHEMBL14293065 | 0.75 | TAAR1 (0.44) | TAAR1AOC3NPC1RAB9AALDH1A1 | |
| SCHEMBL8542576 | 0.75 | RAD52 (0.55) | ALDH1A1KMT2APOLBMAPT | |
| SCHEMBL14292525 | 0.75 | TAAR1 (0.44) | TAAR1AOC3NPC1RAB9AALDH1A1 | |
| SCHEMBL14293074 | 0.75 | TAAR1 (0.44) | TAAR1AOC3NPC1RAB9AALDH1A1 | |
| SCHEMBL15094729 | 0.74 | ESR1 (0.59) | NFKB1KMT2AMAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097378-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8212032-B2 | sEH inhibitors and their use | GLAXOSMITHKLINE LLC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-7994317-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | TAAR1 2622/4885AOC3 619/4885NFKB1 1738/4885 |
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | FAH, NCEH1, SELENOI | TAAR1 3757/4885AOC3 898/4885NFKB1 2702/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | TAAR1 2541/4885AOC3 812/4885NFKB1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.